Dr. Siddiqui on first-line treatments for bladder cancer

“This category of therapeutic is fairly well-tolerated; safe to give,” says Mohummad M. Siddiqui MD.

In this video, Mohummad M. Siddiqui, MD, discusses the main takeaways concerning the bladder cancer therapeutics durvalumab (Imfinzi)/atezolizumab (Tecentriq) and pembrolizumab (Keytruda)/atezolizumab, which were topics focused on during the bladder cancer course presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Siddiqui is an associate professor of surgery and director of urologic oncology and robotic surgery at the University of Maryland, Baltimore.